Screener
Ardelyx ARDX XPHOZAH — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ardelyx in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ardelyx’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437402-26-000044
| (in thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product sales, net | ||||
| IBSRELA | $86,243 | $65,045 | $156,317 | $109,448 |
| XPHOZAH | 31,886 | 25,032 | 55,185 | 48,443 |
| Total product sales, net | $118,129 | $90,077 | $211,502 | $157,891 |
| Product sales, net as a percentage of total revenues | 97.7% | 92.2% | 98.2% | 91.9% |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ardelyx's XPHOZAH — total revenues?
- Ardelyx (ARDX) reported XPHOZAH — total revenues of $31.89M in Q2 2026.
- How has Ardelyx's XPHOZAH — total revenues changed year-over-year?
- Ardelyx's XPHOZAH — total revenues increased by 27.4% year-over-year, from $25.03M to $31.89M.
- What does XPHOZAH — total revenues mean?
- This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic asset within a defined reporting period. It reflects the market adoption, pricing strategy, and commercial success of the product in its target patient population. Investors use this to evaluate the revenue contribution and growth trajectory of a key commercialized asset relative to the company's overall portfolio.
Ask your AI about Ardelyx's xphozah — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude